Barclays PLC Grows Stake in Regulus Therapeutics Inc. (NASDAQ:RGLS)

Barclays PLC raised its holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) by 285.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 84,477 shares of the biopharmaceutical company’s stock after buying an additional 62,549 shares during the quarter. Barclays PLC owned about 0.13% of Regulus Therapeutics worth $132,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the business. Creative Planning bought a new stake in Regulus Therapeutics in the third quarter valued at $26,000. SG Americas Securities LLC purchased a new stake in shares of Regulus Therapeutics in the 3rd quarter worth about $33,000. Jane Street Group LLC purchased a new stake in shares of Regulus Therapeutics in the 3rd quarter worth about $46,000. Rhumbline Advisers bought a new stake in shares of Regulus Therapeutics during the 2nd quarter valued at about $136,000. Finally, Tyche Wealth Partners LLC increased its position in shares of Regulus Therapeutics by 920.6% during the third quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company’s stock valued at $167,000 after buying an additional 95,694 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Preston Klassen sold 31,445 shares of the company’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $39,620.70. Following the transaction, the insider now owns 36,055 shares in the company, valued at $45,429.30. The trade was a 46.59 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Christopher Ray Aker sold 38,547 shares of the stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $1.26, for a total transaction of $48,569.22. Following the sale, the vice president now directly owns 54,634 shares in the company, valued at $68,838.84. This trade represents a 41.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 223,998 shares of company stock worth $282,237 in the last 90 days. Insiders own 4.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a report on Monday, November 11th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $10.80.

Regulus Therapeutics Price Performance

NASDAQ:RGLS opened at $1.21 on Friday. The firm’s 50-day moving average price is $1.50 and its 200-day moving average price is $1.57. The company has a market capitalization of $79.26 million, a PE ratio of -1.13 and a beta of 1.60. Regulus Therapeutics Inc. has a 1-year low of $1.16 and a 1-year high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). Equities analysts anticipate that Regulus Therapeutics Inc. will post -0.88 EPS for the current fiscal year.

Regulus Therapeutics Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.